APA (7th ed.) Citation

H, F., YT, H., & R, S. (2025). Pros and Cons of Inpatient SGLT2i Use for Hyperglycemia and Heart Failure. Journal of the Endocrine Society, 9(2), bvae229. https://doi.org/10.1210/jendso/bvae229

Chicago Style (17th ed.) Citation

H, Fried, Harris YT, and Schulman-Rosenbaum R. "Pros and Cons of Inpatient SGLT2i Use for Hyperglycemia and Heart Failure." Journal of the Endocrine Society 9, no. 2 (2025): bvae229. https://doi.org/10.1210/jendso/bvae229.

MLA (9th ed.) Citation

H, Fried, et al. "Pros and Cons of Inpatient SGLT2i Use for Hyperglycemia and Heart Failure." Journal of the Endocrine Society, vol. 9, no. 2, 2025, p. bvae229, https://doi.org/10.1210/jendso/bvae229.